FDA says it continued to improve the speed and consistency of drug manufacturing oversight in fiscal year 2024, citing strong performance under an int...
FDA cites Asahi Kasei Finechem Co. for significant quality control deficiencies following a November inspection of the companys active pharmaceutical ...
FDAs annual report on drug approvals says the majority of novel drugs approved in 2025 moved through accelerated regulatory pathways.
Advocacy groups urge Congress to advance legislation that would eliminate the statutory distinction between biosimilars and so-called interchangeable ...
Sanofi says its experimental antibody amlitelimab showed consistent efficacy and a favorable safety profile across multiple late-stage clinical trials...
FDA approves Guardant Healths Guardant360 CDx liquid biopsy as a companion diagnostic to identify patients with BRAF V600Emutant metastatic colorectal...
Six King & Spalding attorneys analyze FDA advertising and promotion enforcement letters for drugs and medical devices issued in 2025, noting that the ...
As its NDA is currently under FDA review, Corcept Therapeutics says its experimental drug relacorilant met the overall survival primary endpoint in a ...